MedTrace Logo

Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer

NCT02598310 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-08-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of nab-PTX and trastuzumab for ER negative and HER2 positive operable (tumor size of 3cm or less and N0) breast cancer.

Conditions

  • Breast Cancer
  • Estrogen Receptor Negative Neoplasm
  • HER-2 Positive Breast Cancer

Interventions

DRUG

nab-paclitaxel

nab-paclitaxel 260mg/m2 q3w

DRUG

Trastuzumab

trastuzumab 6 mg/kg (8 mg/kg as the loading dose)

Sponsors & Collaborators

  • Osaka Medical College

    lead OTHER

Principal Investigators

  • Mitsuhiko Iwamoto, MD, PhD · Osaka Medical College

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2018-11-30
Completion
2018-11-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02598310 on ClinicalTrials.gov